Page 8 - Pfizer

EU clears Moderna coronavirus vaccine for young kids, Pfizer boosters

The Pfizer-BioNTech vaccine was previously granted a green light for use in children aged five and over last November

Pfizer Covid vaccine less effective kids aged 5-11 against Omicron: Study

The study examined Pfizer vaccine effectiveness from December 13, 2021 to January 30, 2022, among 852,384 fully-vaccinated children 12-17 years and 365,502 children 5-11 years

Moderna eyes Covid booster by August, not clear yet if Omicron-specific

Moderna chief executive Stephane Bancel said in an interview the company aimed to have a booster ready by August 2022, before next autumn when he said more vulnerable people may need it

Antibodies improve in quality for months after Covid vaccination: Study

The findings, published in the journal Nature, suggest that declining antibody levels in the months after vaccination primarily represent a shift to a sustainable immune response

Covid: China grants conditional approval for Pfizer's oral drug

The pill is a small-molecule oral drug, a co-package of antiviral drugs nirmatrelvir tablets and ritonavir tablets, for adults who are experiencing mild to moderate Covid symptoms

US FDA postpones meeting on authorising Pfizer-BioNTech Covid vax for kids

The US FDA) announced that it has postponed an advisory panel meeting on the use of the Pfizer-BioNTech Covid-19 vaccine in children six months through four years of age, saying it needs more data.

Japan approves Pfizer Covid-19 oral pills amid surging infections

Japan has granted fast-track approval to US drug maker Pfizer Inc.'s COVID-19 pill, the heath minister said Thursday, as the country struggles to slow fast-spreading omicron infections. The approval came less than a month after Pfizer applied in mid-January, an exceptional speed in a country where foreign drug approvals usually take much longer. Health Minister Shigeyuki Goto said the availability of Pfizer's Paxlovid pill gives high-risk patients, including elderly people and those with underlying health issues, greater treatment options. The approval comes as surging cases among elderly patients are starting to overwhelm hospitals in Tokyo and other metropolitan areas, and delayed booster vaccinations have reached only about 8% of the population. Most of Japan's 47 prefectures are currently under a mild version of a state of emergency. On Friday, Prime Minister Fumio Kishida announced plans to extend current restrictions in Tokyo and 12 other areas for three more weeks until Mar

GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off

The results underscore a comeback for GSK in the race to help fight the Covid-19 pandemic after it failed to bring a vaccine to the market so far

Pfizer to rake in earnings of over $100 bn in Covid vax & antiviral pill

On Tuesday, the company revealed its fourth quarter earnings and revenue projections for 2022 where it said it estimates it will earn up to $102 billion in sales next year, which would be a new record

Vaccine sales pushes Pfizer beyond expectations in final quarter

Pfizer said Tuesday that it expects adjusted earnings in the new year to range from USD 6.35 to USD 6.55 per share on USD 98 billion to USD 102 billion in revenue

Pfizer net profit rises 2% at Rs 144 crore in December quarter

Drug firm Pfizer said its net profit increased by 1.89 per cent to Rs 143.91 crore for the third quarter ended December 31, 2021.

France to start using Pfizer's Covid-19 drug this week, first in EU

France says it will start administering Pfizer's coronavirus antiviral drug this week, the first pill for treating Covid-19 approved in the 27-nation EU.

Pfizer applies to USFDA for two-dose vaccine for kids under 5 years

The request for emergency authorisation comes as the highly contagious Omicron variant has led to record numbers of infections

After Pfizer, Moderna starts trial of Omicron-specific Covid vaccine

US drug maker Moderna has started trial of a Covid booster vaccine that specifically targets the Omicron variant, the company has announced.

Moderna starts trial for Omicron-specific booster shot, follows Pfizer

The coronavirus variant has quickly become dominant in many parts of the world, driving up infections and straining healthcare systems.

Pfizer begins testing omicron-matched Covid-19 shots in adults

Pfizer and its partner BioNTech announced the study on Tuesday

Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine

The companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot

Pfizer, CornoaVac vaccine may cause heart inflammation in adolescents

Despite low risk, there is an increased relative risk of carditis - a type of heart inflammation - associated with Covid vaccine developed by Pfizer and China's CoronaVac, researchers have found.

Annual Covid-19 vax preferred to frequent boosters, says Pfizer CEO

Albert Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight Omicron, and mass produce it, as soon as March

Moderna vax may lead to fewer breakthrough Covid infections than Pfizer

Those who have received the Moderna Covid-19 mRNA vaccine are less likely to experience "breakthrough" Covid-19 cases, compared to recipients of the Pfizer-BioNTech mRNA vaccine